Lv11
28 积分 2023-04-13 加入
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
13分钟前
待确认
Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort
2个月前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
2个月前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
2个月前
已完结
Positive results for daraxonrasib for previously treated metastatic pancreatic cancer
2个月前
已完结
Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
3个月前
已完结
Comparison of circulating tumor DNA assays for molecular residual disease detection in non-small cell lung cancer
3个月前
已关闭
First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer
3个月前
已完结
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
3个月前
已完结
Minimal residual disease as a target for liquid biopsy in patients with solid tumours
3个月前
已完结